Searched for
SANOFI DIABETES DRUG
Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 cr from Indian pharma giantsSanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licens...- Sanofi introduces diabetes drug Soliqua in IndiaSanofi India has launched its diabetes drug Soliqua in India, a once-daily injectable combination drug containing insulin and GLP-1 recepto...
- Sanofi looks for accelerated growth in India; plans fast-tracking of product pipelineSanofi, a leading French pharmaceutical company, aims to expand its presence in the Indian market by introducing new drugs, enhancing local...
- Sanofi plans to launch 1 or 2 products in India every yearSanofi prioritizes the Indian market, focusing on diabetes, consumer health, and innovation. With a strategic shift under Hrosz's leadershi...
- Sanofi reinvigorates India business, with eye on higher growthThe company has outlined an ‘India for India’ strategy, where it will focus on diabetes, consumer health, a combination of product innovati...
- French drugmaker Sanofi looks to spin off its consumer business in IndiaThe leading vaccine maker is working with Bank of America on the demerger process, said the people cited above. About 60% of Sanofi India i...
- Sanofi launches new long-acting insulin drug in IndiaSoliqua is indicated as treatment to improve glycemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabete...
- Biocon's partner Mylan gets favourable ruling from US patent authority for 4 devices"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. Thi...
- Sanofi bets on India with portfolio of drugs for diabetes, rare diseasesSanofi reported one of the sharpest falls in its global sales in the fourth quarter, owing to the decline in diabetes drug sales, a controv...
- Regulatory actions won't stop growth of emerging markets, says Sanofi EVPEmerging markets account for 7% of Sanofi’s global revenues, driven by its limited product in rare diseases, diabetes and oncology segments.
- Eli Lilly launches once-a-week diabetes drug in IndiaThe once-a-week non-insulin injectable Trulicity is distinct in the duration of dosage compared to products like Novo Nordisk's Victoza or ...
- Codified rules for doctor-drug firm relations bring transparency, says Christopher ViehbacherInnovative products will not impact diabetes in India on their own. Without proper access to effective care, the epidemic will continue.
- Pharmaceutical companies like Ranbaxy Laboratories, Sanofi India and others fume at price control orderOn Friday, the National Pharmaceutical Pricing Authority (NPPA) slashed the prices of 108 brands under a provision of the Drug Pricing Cont...
- Sanofi India shares tank over 10% on price control orderSanofi India's stock tanked 10.22 per cent to settle at Rs 2,900. In intra-day trade, the scrip plunged 10.99 per cent to Rs 2,875.
- Coming soon: Novo Nordisk’s long-lasting insulin injectionNovo is betting big on Tresiba in the emerging markets after it failed to get an approval for the drug from the US Food and Drug Administra...
- Sanofi charts India-specific strategy to boost shareFrench drug maker Sanofi says it is considering an India-specific strategy to increase its share in the country’s Rs 65,000-crore drug mark...
- NPPA likely to revise prices of 50 drugs soonIndia's drug price regulator, National Pharmaceutical Pricing Authority, is expected to soon revise prices of about 50 medicines, including...
- Pharma companies using 'health managers' to help patients and earn revenuesThe companies give patients more than just the daily dose, helping them with counselling, diagnostic tests, freebies, diet or exercise advi...
- Diabetes drugs post fastest sales growthOral anti-diabetes segment grew 29.7% for the nine-month period ended August 2010 over the year ago period compared with 22.9% increase in ...
- Aventis Pharma, Themis sign tech dealAventis Pharma and Themis Laboratories have signed a technology transfer agreement for fixed-dose combinations comprising glibenclamide (Da...
Load More
